DEF 14A: Calidi Biotherapeutics Sets Date for Virtual Annual Stockholders Meeting

Calidi Biotherapeutics will hold its annual stockholders meeting virtually on September 20, 2024, to vote on the election of directors and ratification of the appointment of auditors.

Summary

• Calidi Biotherapeutics will hold its virtual Annual Meeting of Stockholders on September 20, 2024, at 8:00 a.m. Pacific Time.
• Stockholders of record as of July 30, 2024, are entitled to vote on two proposals: the election of a Class I director and the ratification of the appointment of Marcum LLP as the independent auditor.
• The Board of Directors recommends voting FOR both proposals.
• The proxy materials were first mailed to stockholders around August 20, 2024.
• The meeting will be a completely virtual meeting conducted via live audio webcast.
• The company has opted to provide materials pursuant to the full set delivery option, delivering paper copies of all proxy materials to each stockholder.
• As of the record date, there were 7,758,396 shares of Common Stock issued and outstanding, entitled to vote.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting factual information about the upcoming annual meeting and standard corporate governance matters. It is neither overly positive nor negative.

Positives

• The virtual meeting format expands stockholder access and participation.
• The company is providing paper copies of all proxy materials to each stockholder.
• The Board recommends voting FOR both proposals.

Negatives

• George Ng will allow the term of his directorship position to expire and not seek re-election at the 2024 annual general meeting.

Risks

• The Proxy Statement may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions.
• If a quorum is not present at the Annual Meeting, we expect that the meeting will be adjourned or postponed to solicit additional proxies.

Future Outlook

The company is soliciting proxies for use at the Annual Meeting and will publish final voting results in a Form 8-K filed with the SEC.

Management Comments

• The Board of Directors and management of Calidi Biotherapeutics, Inc. look forward to your attendance at the Annual Meeting.
• We believe that a virtual meeting format expands stockholder access and participation and improves communications.

Industry Context

This is a standard proxy statement for an annual meeting, covering routine matters such as director elections and auditor ratification, which are common practices for publicly traded companies.

Comparison to Industry Standards

• The proxy statement adheres to SEC guidelines and includes standard disclosures expected of publicly traded companies.
• The virtual meeting format is increasingly common among companies seeking to improve accessibility and reduce costs.
• The proposals are typical for an annual meeting, aligning with corporate governance best practices.

Management Changes

Corporate Governance

Legal Proceedings

• Tony Kalajian, our prior chief accounting officer and interim chief financial officer, filed a complaint in the Superior Court of the State of California County of San Diego against us, Mr. Camaisa, our Chief Executive Officer, and Ms. Pizarro, our Chief Administrative Office and Chief Legal Officer, alleging constructive discharge of Mr. Kalajians position of interim Chief Financial Officer and defamation by us, Mr. Camaisa and Ms. Pizarro in connection with Mr. Kalajians alleged discharge.

Stakeholder Impact

• Stockholders are encouraged to participate in the virtual Annual Meeting and vote on the proposals.
• The outcome of the proposals will impact the composition of the Board of Directors and the selection of the independent auditor.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on September 20, 2024.
• The company will file a Form 8-K with the final voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Election of Directors, Ratification of Auditors, Calidi Biotherapeutics, Voting